Effects of CEQUA™ on Objective and Subjective Dry Eye Findings Associated With Sjogren's Syndrome

Who is this study for? Patients with Sjogren's syndrome and ocular dryness
What treatments are being studied? Cyclosporine
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The primary objective of this study is to show that CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: No
View:

• Clinical diagnosis of Sjogren's Syndrome.

• Self-reported complaints of ocular dryness for a period of at least 3 months

• Best-corrected distance visual acuity of 20/25 or better in each eye.

Locations
United States
New York
Center for Ophthalmic and Vision Recearch
Recruiting
Manhattan
Contact Information
Primary
George Zikos, OD, MS
COVR@ea-ny.com
212-650-4888
Backup
John Rocco Robilotto, OD, PhD
COVR@ea-ny.com
212-650-4888
Time Frame
Start Date: June 21, 2021
Estimated Completion Date: June 1, 2023
Participants
Target number of participants: 50
Treatments
Experimental: Cyclosporine
Participants receive Cyclosporine 0.09% Ophthalmic Solution (Cequa), 1 drop, each eye, twice a day for 12 weeks
Authors
George Zikos, John Rocco Robilotto, Hanish Patel
Sponsors
Leads: Center for Ophthalmic and Vision Research, LLC
Collaborators: Sun Pharmaceutical Industries Limited

This content was sourced from clinicaltrials.gov

Similar Clinical Trials